Hutchmed China Ltd - Company Profile
Powered by 
All the sales intelligence you need on Hutchmed China Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Hutchmed China Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Hutchmed China Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Hutchmed China Ltd (Hutchmed) is a biopharmaceutical company that manufactures, discovers, develops, and commercializes drugs for the treatment of solid tumors and hematological malignancies, and immunological disorders. Major products include fruquintinib, an oral inhibitor of vascular endothelial growth factor receptor (VEGFR) 1/2/3; surufatinib, a novel, oral angio-immuno kinase inhibitor that inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR); and savolitinib, an oral selective MET TKI that blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations. It operates in China, North America, Europe, and Australia. The company offers prescription and consumer health drugs to hospitals and through other pharmaceutical companies under the brand names Elunate, Sulanda, and Orpathys, respectively. Hutchmed is headquartered in Hong Kong.
Headquarters
Hong Kong
Address
48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong City
Website
www.hutch-med.com
Telephone
852 212 81188
No of Employees
1,790
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
13 (HKG)
Revenue (2024)
$548.5M
-13%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
1111%
(2024 vs 2023)
Market Cap*
$2.1B
Net Profit Margin (2024)
XYZ
1,290.7%
(2024 vs 2023)
* As of and is in US$
Hutchmed China Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Fruquintinib: For blocking tumor angiogenesis | Fruzaqla |
| Surufatinib: To regulate tumor-associated macrophages | Sulanda |
| Savolitinib: To block atypical activation of the MET receptor tyrosine kinase pathway | Orpathys |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In June, the company and Innovent received NDA acceptance from NMPA for fruquintinib combination with sintilimab for the treatment of advanced renal cell carcinoma. |
| 2025 | Regulatory Approval | In June, the company's NDA for orpathys in combination with tagrisso for the treatment of lung cancer patients with MET amplification after progression on first-line EGFR inhibitor therapy received approval from NMPA. |
| 2025 | Regulatory Approval | In March, the company received NMPA conditional approval for TAZVERIK (tazemetostat) to treat relapsed or refractory follicular lymphoma. |
Competitor Comparison
| Key Parameters | Hutchmed China Ltd | Shanghai Pharmaceuticals Holding Co Ltd | China Resources Pharmaceutical Group Ltd | Beijing Tong Ren Tang Co Ltd | Chongqing Pharmaceutical Group Schiller Medical Equipment Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Hong Kong | China | Hong Kong | China | China |
| City | Hong Kong City | Shanghai | Hong Kong City | Beijing | Chongqing |
| State/Province | - | Shanghai | - | Beijing | Chongqing |
| No. of Employees | 1,790 | 49,608 | 85,600 | 17,284 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Johnny CHENG | Chief Executive Officer - Acting; Chief Financial Officer; Director | Executive Board | - | 59 |
| Steven Hu | Head - Commercial (China); Executive Vice President | Senior Management | - | - |
| Dan Eldar, PhD | Chairman | Non Executive Board | 2024 | 72 |
| Weiguo SU | Chief Scientific Officer; Chief Executive Officer; Director | Executive Board | 2022 | 68 |
| David NG | Head - Investor Relations and Capital Strategies | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer